Nchi: Australia
Lugha: Kiingereza
Chanzo: Department of Health (Therapeutic Goods Administration)
rivastigmine hydrogen tartrate, Quantity: 2.4 mg
Arrotex Pharmaceuticals Pty Ltd
rivastigmine hydrogen tartrate
Capsule
Excipient Ingredients: microcrystalline cellulose; stearic acid; Gelatin; iron oxide yellow; maize starch; titanium dioxide; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; Shellac; strong ammonia solution; iron oxide black; potassium hydroxide
Oral
28, 112, 56, 14
(S4) Prescription Only Medicine
Rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the Alzheimer's type
Visual Identification: Hard gelatine calsule with yellow, opaque body and yellow opaque cap. Imprinted "APO R1.5" in black ink, white to off white fill.; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 12 Months; Container Temperature: Store below 25 degrees Celsius
Registered
2010-07-27